Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotech advancing novel therapies for fibro-inflammatory diseases. This news hub provides investors and researchers with essential updates on nebokitug (CM-101), the company's lead monoclonal antibody targeting CCL24 in conditions like primary sclerosing cholangitis (PSC) and systemic sclerosis.
Access timely reports on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes verified updates from Phase 2/3 trials, FDA/EMA designations, and scientific conference presentations. Key focus areas span biomarker validation, trial enrollment status, and intellectual property developments.
This resource serves as your central source for tracking Chemomab's progress in addressing high-need rare diseases. Bookmark this page for direct access to primary documents including SEC filings, peer-reviewed data publications, and official press releases. Check regularly for updates on the upcoming Phase 3 PSC trial and expansion into new fibrotic disease indications.
Chemomab Therapeutics (Nasdaq: CMMB) presented positive Phase 2 SPRING trial data for nebokitug (CM-101) in primary sclerosing cholangitis (PSC) at BSG Live'25. The data was presented by Principal Investigator Dr. Douglas Thorburn at the British Society for Gastroenterology annual meeting in Glasgow.
The trial demonstrated that nebokitug was well-tolerated over 48 weeks of treatment, with a safety profile comparable to placebo during the initial 15-week double-blind portion. In patients with moderate to advanced disease, the drug showed dose-dependent anti-inflammatory, anti-fibrotic, and anti-cholestatic effects.
The open-label extension portion, lasting up to an additional 33 weeks, revealed sustained improvement in fibrosis markers and other PSC-related parameters. These positive results support advancement to Phase 3 trials, potentially positioning nebokitug as the first approved therapy for PSC.
Chemomab Therapeutics (Nasdaq: CMMB) has presented new positive clinical data at EASL 2025 supporting nebokitug's potential as a first-in-class treatment for Primary Sclerosing Cholangitis (PSC) and related fibro-inflammatory diseases.
The Phase 2 SPRING trial analysis revealed that nebokitug treatment resulted in dose-dependent improvements in multiple inflammatory and fibrotic biomarkers. A comprehensive proteomic analysis of 3,000 circulating proteins showed significant changes in proteins related to fibrosis, immune cell recruitment, and inflammation. The treatment led to downregulation of biological processes including cell-cell adhesion, extracellular matrix organization, and pathways involved in leukocyte migration.
Pharmacokinetic analyses demonstrated dose-proportional increases in nebokitug concentration, with steady-state levels achieved after the fourth dose. Linear regression analyses indicated trends between increasing patient exposure to nebokitug and decreasing levels of PSC disease biomarkers, including liver enzyme and transient elastography scores.
Chemomab Therapeutics (Nasdaq: CMMB) has announced upcoming presentations of clinical data for nebokitug (CM-101) in treating primary sclerosing cholangitis (PSC) at three major scientific conferences.
The presentations will take place at:
- DDW25 (May 3-6, 2025, San Diego) featuring an oral presentation by Dr. Paul Pockros on safety, tolerability, and biomarker improvements
- EASL 2025 (May 7-10, 2025, Amsterdam) with two poster presentations by CEO Adi Mor on pharmacokinetics, pharmacodynamics, and proteomic profile changes
- BSG LIVE'25 (June 23-26, 2025, Glasgow) featuring an oral presentation by Prof. Douglas Thorburn on the SPRING Study results
The presentations will focus on CM-101's impact on inflammation, fibrosis, and cholestasis in PSC patients.
Chemomab Therapeutics (Nasdaq: CMMB) has announced key leadership changes in its medical and clinical teams. David M. Weiner, MD, has been appointed as Interim Chief Medical Officer, returning to a role he previously held in 2021-2022. Additionally, Jack Lawler has been promoted to Chief Development Officer.
Dr. Weiner brings over 25 years of experience in therapeutic discovery and clinical development, replacing Matt Frankel, MD. Lawler, who joined Chemomab in 2022, has been credited with leading the successful Phase 2 SPRING trial for nebokitug in primary sclerosing cholangitis (PSC).
The appointments come at a important time following the company's successful completion of the Phase 2 PSC program. Nebokitug has shown potential to become the first FDA-approved drug for PSC with disease-modifying activity. The company is currently planning its next steps following these positive clinical results.
Chemomab Therapeutics (Nasdaq: CMMB) has reported positive results from the Open Label Extension (OLE) portion of its Phase 2 SPRING trial for nebokitug in primary sclerosing cholangitis (PSC) patients. The trial showed continued improvements across key liver biomarkers after 48 weeks of treatment.
Key findings include:
- Over 90% of eligible SPRING trial patients participated in the OLE
- Patients with moderate/advanced disease showed significantly lower clinical events (4.8%) compared to historical controls (25.8%)
- Treatment demonstrated improvements in liver injury, inflammation, and fibrosis markers
- The drug was well-tolerated at both 10 mg/kg and 20 mg/kg doses administered every three weeks
The results support nebokitug's potential to become the first approved drug with disease-modifying activity for PSC, a deadly disorder currently lacking effective treatments. The 20 mg/kg dose showed particularly strong results and will be used in the upcoming Phase 3 trial.
Chemomab Therapeutics (Nasdaq: CMMB) presented new data at CORA 2025 supporting the potential of nebokitug (CM-101) as a treatment for systemic sclerosis (SSc). The presentation, scheduled for March 8, 2025, in Venice, Italy, showcases nebokitug as a first-in-class monoclonal antibody targeting CCL24, a key driver in fibro-inflammatory conditions.
The new study, conducted with Dr. Alexandra Balbir-Gurman, analyzed skin and serum samples from SSc patients and demonstrated CCL24's role in induced fibrosis and SSc pathogenesis. A 2024 peer-reviewed study of over 200 SSc patients showed that higher CCL24 levels correlated with severe SSc forms and predicted pulmonary function deterioration and higher 10-year mortality.
Recent positive results from the Phase 2 SPRING trial in PSC patients demonstrated nebokitug's effectiveness in reducing fibro-inflammatory biomarkers, including ELF score, PRO-C3, IL-6, and TGF-β, which are also indicators of SSc activity.